- Learn how real-world data is transformed into structured, usable intelligence through PRISM (Patient Record Inference & Structuring Module), an AI-enabled engine that converts fragmented, multi-modal patient data into inference-ready patient journeys supporting scalable clinical insights and model validation.
- Explore how Zephyr’s AI-enabled multi-modal models (AIM Suite) predict drug response and reconstruct gene expression from clinically available inputs, such as NGS data from commercial LDTs and whole-slide images, enabling retrospective and prospective evaluation of treatment predictions across oncologic therapeutic classes.
- Discover how Zephyr’s AI-driven software accelerates co-development and clinical integration, enabling fine-tuned foundation models to embed directly into R&D workflows while supporting rapid clinical intelligence queries, cohorting, and data-driven decision-making.
Anshu Jain, MD
Dr. Anshu Jain is Zephyr AI’s Chief Business and Clinical Officer. A double board-certified radiation oncologist and clinical informatician, he leads business development, clinical strategy, medical affairs, and partner collaborations—translating Zephyr’s AI and large-scale real-world data into solutions that help biopharma and diagnostic partners advance precision medicine for patients. Prior to Zephyr, Dr. Jain served as Chief Medical Officer at Aster Insights.
Dr. Jain has authored peer-reviewed publications in Nature Communications, Journal of Clinical Oncology (JCO), and JCO Clinical Cancer Informatics, and has served as a principal investigator for early- and late-phase oncology trials. He has advised the FDA Office of the Commissioner and the Oncology Center of Excellence, and provided clinical leadership to large-scale data initiatives including the NCI SEER program.
He serves on the Board of Directors of the Community Oncology Alliance, the Board of Advisors for the Duke Cancer Institute, and is an Assistant Professor at the Yale School of Medicine.
Dr. Jain trained in internal medicine and radiation oncology at the Massachusetts General Hospital and Columbia New York Presbyterian Hospital. He earned his M.D. with Highest Distinction from the University of Kentucky College of Medicine and a degree in Economics from Duke University.
Zephyr AI
Website: www.zephyrai.bio
Zephyr AI is a precision-medicine company unifying enterprise-scale real-world data with multi-modal AI to deliver actionable, biologically interpretable insights across the therapeutic lifecycle—from discovery to clinical deployment. Our software-native, AI-enabled modules predict drug response and reconstruct gene-expression signatures from clinically available DNA-based inputs and drug metadata, and can be fine-tuned to novel therapeutics or diagnostics. Pilots stand up in weeks, informing patient stratification, trial optimization, label expansion, and indication discovery.
PRISM, our SOC 2/HIPAA-aligned data and compute infrastructure, powers rapid cohort construction, synthetic control arms, and real-world validation with intervention-specific risk modeling. Through Aster Insights™ and the ORIEN Total Cancer Care® study, Zephyr provides access to deeply annotated oncology assets—lifetime-consented patients with linked clinical, exome, transcriptome, and whole-slide imaging—to enable fit-for-purpose data generation. We partner with biopharma, diagnostics, and digital-pathology leaders, integrating seamlessly into existing workflows with no new assays required. Together with a rigorous validation engine grounded in real-world outcomes, Zephyr bridges experimental and clinical domains to extract signal from heterogeneous data, de-risk development, and bring effective therapies to patients sooner. Our mission is to make precision medicine accessible and immediate—turning fragmented data into confident, patient-impacting decisions at scale.
